EU/3/17/1843:

Soluble recombinant human fibroblast growth factor receptor 3

Overview

On 27 February 2017, orphan designation (EU/3/17/1843) was granted by the European Commission to TherAchon SAS, France, for soluble recombinant human fibroblast growth factor receptor 3 (also known as rhFGFR3) for the treatment of achondroplasia.

The sponsorship was transferred to Pfizer Europe MA EEIG in November 2019.

Key facts

Active substance
Soluble recombinant human fibroblast growth factor receptor 3
Intented use
Treatment of achondroplasia
Date of designation
27/02/2017
Orphan designation status
Positive
EU designation number
EU/3/17/1843

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product it it is approved for marketing authorisation.

Sponsor's contact details

Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgium
E-mail: orphan_enquiries@pfizer.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating